carivalan 12,5 mg/5 mg filmtabletta
les laboratoires servier - carvedilol; az ivabradin -
carivalan 12,5 mg/7,5 mg filmtabletta
les laboratoires servier - carvedilol; az ivabradin -
carivalan 25 mg/5 mg filmtabletta
les laboratoires servier - carvedilol; az ivabradin -
carivalan 25 mg/7,5 mg filmtabletta
les laboratoires servier - carvedilol; az ivabradin -
dalacin 10 mg/ml külsőleges emulzió
pfizer kft. - clindamycin -
dalacin 10 mg/ml külsőleges oldat
pfizer kft. - clindamycin -
dalacin 20 mg/g hüvelykrém
pfizer kft. - clindamycin -
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - daganatellenes szerek - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
adempas
bayer ag - riociguat - magas vérnyomás, pulmonalis - a magas vérnyomáscsökkentők a pulmonalis artériás hipertónia számára - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. hatékonyságát igazolta, hogy a pah lakosság, beleértve a etiológiájú, idiopátiás, vagy örökölhető pah, vagy pah kapcsolódó kötőszöveti betegség. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
solymbic
amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - immunszuppresszánsok - kérjük, olvassa el a 4. részt. a termékinformációk összefoglalójának 1. pontja a termékinformációs dokumentumban található.